» Articles » PMID: 27402921

Impact of Cardiovascular Risk Factors on Graft Outcome Disparities in Black Kidney Transplant Recipients

Overview
Journal Hypertension
Date 2016 Jul 13
PMID 27402921
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Although outcome inequalities for non-Hispanic black (NHB) kidney transplant recipients are well documented, there is paucity in data assessing the impact of cardiovascular disease (CVD) risk factors on this disparity in kidney transplantation. This was a longitudinal study of a national cohort of veteran kidney recipients transplanted between January 2001 and December 2007. Data included baseline characteristics acquired through the United States Renal Data System linked to detailed clinical follow-up information acquired through the Veterans Affairs electronic health records. Analyses were conducted using sequential multivariable modeling (Cox regression), incorporating blocks of variables into iterative nested models; 3139 patients were included (2095 non-Hispanic whites [66.7%] and 1044 NHBs [33.3%]). NHBs had a higher prevalence of hypertension (100% versus 99%; P<0.01) and post-transplant diabetes mellitus (59% versus 53%; P<0.01) with reduced control of hypertension (blood pressure <140/90 60% versus 69%; P<0.01), diabetes mellitus (A1c <7%, 35% versus 47%; P<0.01), and low-density lipoprotein (<100 mg/dL, 55% versus 61%; P<0.01). Adherence to medications used to manage CVD risk was significantly lower in NHBs. In the fully adjusted models, the independent risk of graft loss in NHBs was substantially reduced (unadjusted hazard ratio, 2.00 versus adjusted hazard ratio, 1.49). CVD risk factors and control reduced the influence of NHB race by 9% to 18%. Similar trends were noted for mortality, and estimates were robust across in sensitivity analyses. These results demonstrate that NHB kidney transplant recipients have significantly higher rates of CVD risk factors and reduced CVD risk control. These issues are likely partly related to medication nonadherence and meaningfully contribute to racial disparities for graft outcomes.

Citing Articles

Multifaceted Intervention to Improve Graft Outcome Disparities in African American Kidney Transplants (MITIGAAT Study): Protocol for a Randomized Controlled Trial.

Overstreet M, Culpepper H, DeHoff D, Gebregziabher M, Posadas Salas M, Su Z JMIR Res Protoc. 2024; 13:e57784.

PMID: 39388231 PMC: 11502971. DOI: 10.2196/57784.


Racial Differences in Medication Utilization for Secondary Prevention of Cardiovascular Disease in Kidney Transplant Recipients: A Post Hoc Analysis of the FAVORIT Trial Cohort.

Fallahzadeh M, Ku E, Chu C, McCulloch C, Tuot D Kidney Med. 2022; 4(4):100438.

PMID: 35360084 PMC: 8961224. DOI: 10.1016/j.xkme.2022.100438.


Racial Difference in the Association of Long-Term Exposure to Fine Particulate Matter (PM) and Cardiovascular Disease Mortality among Renal Transplant Recipients.

Dehom S, Knutsen S, Bahjri K, Shavlik D, Oda K, Ali H Int J Environ Res Public Health. 2021; 18(8).

PMID: 33919563 PMC: 8073484. DOI: 10.3390/ijerph18084297.


Glycemic management and clinical outcomes in underserved minority kidney transplant recipients with type 2 and posttransplantation diabetes: A single-center retrospective study.

Aleksic S, Eisenberg R, Tsomos E, Zahedpour Anaraki S, Japp E, Upadhyay L Diabetes Res Clin Pract. 2020; 165:108221.

PMID: 32442553 PMC: 7415727. DOI: 10.1016/j.diabres.2020.108221.


Pharmacist-Led, Technology-Assisted Study to Improve Medication Safety, Cardiovascular Risk Factor Control, and Racial Disparities in Kidney Transplant Recipients.

Taber D, Gebregziabher M, Posadas A, Schaffner C, Egede L, Baliga P J Am Coll Clin Pharm. 2019; 1(2):81-88.

PMID: 30714026 PMC: 6350824. DOI: 10.1002/jac5.1024.


References
1.
Opelz G, Mickey M, Terasaki P . Influence of race on kidney transplant survival. Transplant Proc. 1977; 9(1):137-42. View

2.
Malat G, Culkin C, Palya A, Ranganna K, Anil Kumar M . African American kidney transplantation survival: the ability of immunosuppression to balance the inherent pre- and post-transplant risk factors. Drugs. 2009; 69(15):2045-62. DOI: 10.2165/11318570-000000000-00000. View

3.
Chisholm-Burns M, Spivey C, Rehfeld R, Zawaideh M, Roe D, Gruessner R . Immunosuppressant therapy adherence and graft failure among pediatric renal transplant recipients. Am J Transplant. 2009; 9(11):2497-504. DOI: 10.1111/j.1600-6143.2009.02793.x. View

4.
Taber D, Gebregziabher M, Srinivas T, Chavin K, Baliga P, Egede L . African-American race modifies the influence of tacrolimus concentrations on acute rejection and toxicity in kidney transplant recipients. Pharmacotherapy. 2015; 35(6):569-77. PMC: 4534305. DOI: 10.1002/phar.1591. View

5.
Carpenter M, Weir M, Adey D, House A, Bostom A, Kusek J . Inadequacy of cardiovascular risk factor management in chronic kidney transplantation - evidence from the FAVORIT study. Clin Transplant. 2012; 26(4):E438-46. PMC: 4388027. DOI: 10.1111/j.1399-0012.2012.01676.x. View